What does the 2026 health insurance premium rise mean for ASX health insurance stocks?

The 2026 health insurance premium rise is in, and it is 4.41%. It made headlines because it is ahead of inflation and the largest average increase in percentage terms since 2017. Obviously unwelcome timing for households struggling with the cost of living, but good for the companies themselves, right? Not so fast.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

The 2026 health insurance premium rise

The 4.41% is the industry weighted-average. But each health insurance fund sets its own rate. Some of the majors are going even higher including NIB (5.47%), AIA (5.98%), Medibank (5.1%), HCF (4.96%) and Bupa (4.8%) are all above that average, while smaller funds like GMHBA (1.98%) and HBF (2.15%) have kept increases well below it.

We noted above the concerns about the cost living. For a typical individual on a gold hospital policy, the annual cost could rise by around $167, while families on a similar policy may pay roughly $330 more per year.

On the other hand, benefits have grown at roughly double the rate of premiums for two years, and as Australia’s population ages and undergoes elective surgery at a greater rate, claims costs are expected to keep rising. But one quick rise will solve it all – not so fast.

Not necessarily good news

There are a number of risks. The first and most obvious risk facing health insurers is member attrition. A 5.1% increase from Medibank or 5.47% from NIB, both well above the industry average, gives cost-conscious policyholders a strong incentive to shop around or drop cover altogether.

In a cost-of-living environment already squeezing household budgets, the April 1 renewal date functions as an annual churn event. Every lapsed policy doesn’t just reduce premium income — it removes a member who, statistically, may have been a low-claimant, leaving a pool that skews older and sicker. That dynamic quietly erodes underwriting margins even as headline revenue rises.

The second and deeper problem is that the premium increase may simply not be enough. This is where last year’s collapse of Healthscope is instructive, not as a warning about insurers directly, but as a window into the structural cost inflation running through the entire private healthcare ecosystem that ultimately flows back to hit insurer claim books.

Healthscope’s CEO was blunt about who he blamed: he accused private health insurers of “banking record profits while refusing to pay fairly” for hospital care, and the stand-off eventually saw Healthscope terminate its contracts with Bupa and the Australian Health Services Alliance — leaving more than six million Australians facing out-of-pocket uncertainty.

An eroding value proposition (potentially)

The reality is that if hospitals are unviable, they close. And if they close, the value proposition of private health insurance, namely faster access to elective procedures, choice of specialist, private rooms diminishes. And if that value proposition erodes, more Australians conclude their premiums are not worth paying.

Private health insurance uptake has already declined steadily in recent years, particularly among younger Australians who view it as an unnecessary cost in the face of rising living expenses — and that fall in insured patients leads directly to a reduction in elective surgeries, the lifeblood of private hospital income. It is a self-reinforcing spiral.

The total funding flowing to private hospitals across all sources — including the federal government’s rebate — now reaches into the tens of billions annually, and some insurers have called for even more taxpayer support to shore up rebates. Premium rises alone (at least not those in the single digits) will solve the funding gap.

For investors in health insurance stocks such as NIB and Medibank, that gap between what is approved and what costs actually demand is the central, under appreciated risk sitting behind both stocks.

Anything to be concerned about?

Let’s look at both of these companies.

NIB

We noted NIB’s health insurance premium rise was 5.47%. The irony is that more than half of NIB’s policyholders will get a rise of $3.80 a week or less. But there is of course a point where it becomes cheaper to just cop the Medicare levy surcharge.

The good news is that nib entered this pricing cycle in strong operational shape. The group’s underlying operating profit surged 22% to $129.1m in H1 FY26, supported by top-line revenue growth of 7.7%, and total persons covered increased 1.9% to a record 1.95 million.

Crucially, the business is extracting meaningful productivity gains — 94% of claims are processed within 24 hours and 86% are processed unassisted using automation, while cumulative productivity savings since FY24 total $39m and have pushed the group operating expense ratio down 100 basis points. For FY26, nib has guided group underlying operating profit in the range of $257–$260m, and expects to continue delivering above-system policyholder growth while maintaining a stable full-year underlying net margin in the 6–7% target range.

The key risk for investors is lapse rates. As the highest-priced major fund, nib is most exposed to members reviewing their cover in April. The near-term investment thesis centres on managing lapse rates and elevated claims inflation as the key catalyst and risk, and investors should be aware that if lapse rates in Australian Residents Health Insurance keep rising in response to premium changes, the investment case becomes more complicated.

NIB has also sold its World Nomads international travel business and is conducting a strategic review of its remaining travel operations, a portfolio simplification that coincides with nib’s focus on growing the core health business. Stripping out travel, the underlying health book is performing, but the stock has lagged the broader market — NIB exceeded the Australian insurance industry’s return of -10.7% over the past year but underperformed the Australian market, which returned 12%.

Medibank

Medibank (ASX:MPL) is Australia’s largest private health insurer by membership, and the 2026 premium cycle has been kind to its share price. The day Medibank confirmed its 5.10% average increase for both Medibank and ahm branded policies, effective 1 April 2026, its shares rose more than 7%. Clearly a signal that markets view the approved rate as sufficient to support margin stability in an environment of rising claims.

The half-year results reinforced that confidence. Medibank reported a 6.0% rise in group operating profit to $381.7 million for the half year to December 31, 2025, and lifted its fully franked interim dividend by 6.4% to 8.3 cents per share — the sixth consecutive annual dividend increase. The insurer also reported net resident policyholder growth of 38,300, or 1.9%, over the half-year period — more than double the increase recorded in the same period a year earlier.

A standout feature of Medibank’s result is the growing contribution from health services. The Medibank Health segment delivered a profit jump of 28.5%, reaching $48.3 million, and now contributes approximately 13% of total group profit, representing a meaningful and growing diversification away from pure underwriting risk. The Amplar Health division’s expansion into primary care also positions Medibank to capture more of the broader healthcare value chain, which is a structural growth story beyond annual premium rounds.

Operational discipline is evident through $125 million in cumulative cost savings over 8.5 years, maintaining one of the lowest expense ratios in the sector — protecting margins as claims inflation remains a structural challenge. Over the past 12 months, Medibank shares have risen 21%, significantly outpacing the S&P/ASX 200’s 7% gain over the same period.

Conclusion

Investors in healthcare insurance stocks seem pleased for now, but they should still be cautious about the risk of member attrition and the structural gap in private hospital funding.

Let’s conclude by answering a question we think many investors are wondering in light of what we wrote about two companies: Which one is better?

Overall, Medibank is the more defensive of the two listed health insurers: bigger membership base, stronger brand diversification across Medibank and ahm, a growing health services division, and a longer dividend track record.